Introduction: Many devices (e.g., nebulizers and spacers) are used to deliver aerosol in a
INTRODUCTION
Aerosols are commonly used with mechanically ventilated patients [1, 2] . They are delivered by a metered dose inhaler (MDI) with or without spacer modification to be used in ventilator circuits or by nebulizers [1, 2] . Previous studies using patients with stable asthma [3] and COPD [4] confirmed that aerosol delivery in bilevel positive airway pressure (BiPAP) non-invasive ventilation circuit (NIV) is feasible and can be effective. Many studies had compared the use of different nebulizers [2, [4] [5] [6] [7] [8] [9] and different spacers [10] [11] [12] [13] [14] [15] breath-by-breath basis by measuring the resistance in the subject's breathing, changing its level over time [16, 17] . Some ventilators include more modalities of ventilation including CPAP and Auto-CPAP.
Additionally, jet nebulizers should ideally be replaced by inhalers which do not distribute aerosol into the environment, e.g., MDI spacers or valve holding chambers when treating patients with, for example, Middle East respiratory syndrome [18] .
The European Respiratory Society Guidelines on the use of nebulizers [19] recommend the determination of the aerodynamic characteristics of the droplets in the emitted dose. However, it had been reported that the Comité-Européen-Normalisation (2001) (CEN) method to measure the aerodynamic characteristics, proposed by the Guidelines [19] , should not be used due to the effects of evaporation. Instead the use of a cooled Next Generation Impactor is recommended [20] . The Anderson Cascade Impactor (ACI) was also validated to measure the aerodynamic characterization of the dose delivered by nebulizers [21] . Only the CEN method that identifies the fate of the nebulized dose using sinus flow breath simulation, and filters to entrain the inhalation and exhalation output of a nebulized, dose should be used.
The aim of the present work was to identify equivalent doses for COPD Auto-CPAP NIV patients due to the reported differences in output and performance between different nebulizers [20, 22] and different spacers [1, 23] . This article does not contain any new studies with human or animal subjects performed by any of the authors.
METHODS

Delivery Systems
A 10,000 lg (in 2 ml) salbutamol respiratory [1, 20, [22] [23] [24] [25] .
In-Vitro Fate of the Aerosolized Dose Using an Automatic Continuous Positive Airway Pressure (Auto-CPAP) System Used for NIV Each of the seven aerosol delivery methods (previously described) were assembled according to Fig. 1 which was designed to mimic that of a patient receiving NIV [5] .
A breathing simulation machine (model 5600i, Grand Rapids, USA) was connected to an Auto-CPAP (3B Medical, Lake Wales, USA) (Fig. 1) The ACI, with its plates in situ, was placed in a refrigerator at 5°C for 60 min before use [21] . Hence, the induction port of the ACI was connected directly into the NIV circuit with an air-tight seal. The vacuum flow through the ACI apparatus was provided by a vacuum pump (Brook Crompton, Huddersfield, UK). The flow rate was measured using an electronic digital flow meter (MKS Instruments, Andover, USA).
For each aerosol delivery method three determinations were made (n = 3). The time to start the Auto-CPAP and breathing machine and the doses delivered by the nebulizers and the spacers as described in the previous section. acetonitrile. Similarly, the mass entrained on the filters was recovered by sonication and rinsing. HPLC used as described in the previous section.
The fine particle dose (FPD), fine particle fraction (FPF %) and the mass median aerodynamic diameter (MMAD) was determined using Copley Inhaler Testing Data Analysis Software (CITDAS, Copley Scientific, Nottingham, UK) impactor data analysis software.
Statistical Analysis
All data are expressed as mean (SD). One-way analysis of variance (ANOVA) with the application of least significant difference correction was used to compare the seven different aerosol delivery methods with SPSS V17.0 (SPSS Inc., Chicago, USA). Table 1 provides a summary of the fate of the delivered dose. No salbutamol was recovered from the ventilation filter or the tubing between this filter and the expiration port. No salbutamol was recovered from the expiration port filter when using any of the spacers to deliver the inhaled dose. Statistical analysis revealed that there was a significant (p\0.001) difference in the amounts recovered on the inhalation filters (Total emitted dose) between the seven methods. Similarly there were significant differences (p\0.001) for the residual volumes and the amount deposited in the T-piece and the amount deposited on the spacer. For the three vibrating mesh nebulizers used there was significantly more (p\0.001) salbutamol entrained on the inhalation filter compared to the jet nebulizer. In addition, the amounts deposited on the tubing and expiration port were significantly greater (p\0.001) for the three vibrating mesh nebulizers, but amounts left in the nebulizer was significantly greater (p\0.001) for SIDE.
RESULTS
As shown in Table 1 , we used percentage to compare the nebulizers to the spacers. The three spacers used had higher percentages of salbutamol deposited on the inhalation filter (p\0.001) compared to the nebulizers. In addition, the percentages of salbutamol entrained in the spacer were higher than those However, the percentages of salbutamol deposited on the tubing and the exhalation port filter were higher for the nebulizers (p\0.001). No significant difference between the three vibrating mesh nebulizers as well as between all the three spacers in all parameters.
The aerodynamic droplet size distribution from each aerosol delivery method is shown in Fig. 3 with a summary in Table 2 . Consistent with the above results no drug was recovered on the ventilation filter or deposited in the tubing of the NIV circuit between the expiration port and ventilator. In addition, no salbutamol was recovered from the expiration port filter when using any of the spacers to deliver the inhaled dose. The FPF of SIDE was the highest (p = 0.021), MMAD of the AC and MC spacers was the smallest (p = 0.001) and the FPD from the SOLO nebulizer was the greatest (p\0.02).
The NIVO had relatively smaller FPF and FPD compared to the other two vibrating mesh nebulizers, but there was no significant difference.
All of the spacers used had a smaller MMAD (p = 0.001) and relatively higher FPF, but not significant, compared to the three vibrating mesh nebulizers used. The VC resulted in aerosol with relatively higher MMAD and lower FPF than the AC and the MC, but was not significant.
DISCUSSION
Placing either the Aerogen Pro, as a vibrating mesh nebulizer, or the Sidestream, as a jet nebulizer between expiration port and breathing simulator was previously proven to produce a higher delivery of the drug to the inhalation filter with less lost through the Table 1 Mean (SD) fate, in lg, and its percentage of the dose delivered using seven different inhalation methods (n = Tubing is that recovered from the nebulizer t-piece and the NIV tubing Sidestream were 4.5 and 3.9 lm, respectively, which is comparable to our previous study using a BiPAP NIV circuit [5] . However, in an earlier study using the same method and nebulizer without the NIV, MMADs were 5.0 and 4.2 lm [20] respectively. In addition FPF in the NIV circuit was higher. Similar to other previous studies [26] these variations show that evaporation could really occur in the NIV circuit. This suggests that aerosol delivery to the lungs of NIV patients would be better than when a patient uses the conventional nebulization method [5] . In addition, it is advisable to remove the humidifier (which might increase the droplet size by condensation), that many patients using CPAP Fig. 3 The mean (SD) aerodynamic distribution of the droplets aerosolized from the seven different aerosol delivery methods using the Anderson Cascade Impactor methodology (n = 3) are utilizing, when a bronchodilator is administered [17] .
No salbutamol was found on the ventilator filter or tubing between this filter and the expiration port. This was due to the 840 ml inner volume of the NIV tubing and the 500 ml The results of the three tested spacers were comparable in all the parameters. The spacers used showed no significant deposition on the expiration port filter at all. This could be attributed to the release of all the MDI delivered doses in the spacers at the start of the inspiratory phase allowing the entire delivered dose to be directed to the patient [31] . The TED deposited on the inhalation filter of the spacers used was about one-fifth and one-third of that of the vibrating mesh nebulizer and the jet nebulizer, respectively. However, the nominal dose placed into the nebulizer was about seven times that placed in the spacer. This resulted in an average TED % from the spacer that was 1.5-fold that of the vibrating mesh nebulizers and 2.5-fold that of the jet nebulizer. These results suggest that approximately 2 mg delivered from a spacer would be equivalent to 3 mg nebulized from a vibrating mesh nebulizer and 5 mg nebulized from a Sidestream. Ari et al. [25] in the BiPAP NIV circuit; showed that the delivery efficiency with the MDI was threefold greater than with the jet nebulizer (p = 0.002).
In addition, about 50% of the delivered dose was deposited on the wall of the spacers tested.
It is well known that particles deposited in the spacer have a very large aerodynamic particle size that would not reach the lung and could cause adverse effect. Hence, spacers could decrease the unwanted adverse effect when used to deliver aerosol in the NIV circuit compared to the nebulizer. In addition, all the spacers tested resulted in very small MMADs compared to all the nebulizers tested. This suggests that evaporation effects were more prominent due to the longer distance of the actuated dose in the spacer to the ACI, resulting in further evaporation. The large amount of drug with large particle size deposited on the wall of the spacer, the better TED % and the smaller MMAD from the spacers used could suggest better lung deposition with lower dose and lower side effect when using a spacer in a NIV.
A study by Power et al. [27] showed a superiority of the NIVO vibrating mesh nebulizer over the jet nebulizer and the MDI in the percentage of the aerosol delivered to the patient when placed in the NIV [27] . Power et al. did not state when they actuated the dose (Perhaps during the expiratory phase). In addition, they did not use a spacer which might improve their MDI results. An additional variable could be the types of salbutamol used in the study as it is known that different types of salbutamol have variable aerosol characteristics [32] . Hence, this may add some variation to the results provided from the MDI with spacers and nebulizers.
The seven tested inhalation device are often used in similar clinical conditions. However, according to our results, to deliver 2 mg (20 doses) efficiently by the spacer to the NIV patient, health care providers need to stand for more than 1 min (about 80 s), as they have to adjust the actuation of each dose at the start of the inspiratory phase. Hence, they need to be focused when delivering 2 mg by a spacer to result in a comparable lung deposition of 3 mg aerosolized by a vibrating mesh nebulizer or 5 mg by a jet nebulizer, which only requires a press of a button to start delivering the dose.
Hence, using spacers might be considered time consuming to the health care provider. This, together with the significant differences in the aerodynamic properties of the delivered dose from the jet nebulizers, vibrating mesh nebulizers and spacers tested in a NIV circuit, highlights why preliminary in vitro data is required for all inhalation delivery methods before introduction in the NIV. 
CONCLUSIONS
